Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 1168 |
| PDBID: | 4ZYP |
| Chains: | NO_B |
| Organism: | Human respiratory syncytial virus A2, Tequatrovirus T4, Mus musculus, Homo sapiens |
| Method: | XRD |
| Resolution (Å): | 5.50 |
| Reference: | 10.1371/journal.ppat.1005035 |
| Antibody | |
| Antibody: | Motavizumab Fab |
| Antibody mutation: | No |
| INN (Clinical Trial): | Motavizumab(Phase-III) |
| Antigen | |
| Antigen: | respiratory syncytial virus (RSV) Fusion glycoprotein F0 |
| Antigen mutation: | No |
| Durg Target: | P03420; P11209; P03420; P11209; |
Sequence information
Antibody
Heavy Chain: N
Mutation: NULL
| >4ZYP_N|Chain D[auth J], L[auth K], N|Motavizumab antibody Fab heavy chain|Mus musculus (10090) QVTLRESGPALVKPTQTLTLTCTFSGFSLSTAGMSVGWIRQPPGKALEWLADIWWDDKKHYNPSLKDRLTISKDTSKNQVVLKVTNMDPADTATYYCARDMIFNFYFDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDK |
Light Chain: O
Mutation: NULL
| >4ZYP_O|Chain E[auth L], M, O|Motavizumab antibody light chain|Mus musculus (10090) DIQMTQSPSTLSASVGDRVTITCSASSRVGYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCFQGSGYPFTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
Antigen
Chain: B
Mutation: NULL
| >4ZYP_B|Chain A, B, C|Fusion glycoprotein F0,Fibritin|Human respiratory syncytial virus A (strain A2) (11259) QNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQSTPATNNRARRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLSAIGGYIPEAPRDGQAYVRKDGEWVLLSTFLGGLVPR |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| N: ALA32 GLY33 TRP52 TRP53 ASP54 LYS56 HIS58 ILE97 PHE98 ASN99 O: ARG29 GLY31 TYR32 HIS34 ASP50 GLY91 SER92 GLY93 TYR94 B: LYS176 SER255 LEU258 SER259 ASN262 ASP263 THR267 ASN268 ASP269 LYS271 LYS272 LEU273 SER275 ASN276 ILE309 ASP310 THR311 ARG364 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)
